Shots:
- A management-led syndicate, supported by global investors, will acquire a majority stake in HistoSonics for $2.25B
- The acquisition was led by K5 Global, Bezos Expeditions, Wellington Management, Alpha JWC Ventures, Venture Investors Health Fund, Lumira Ventures, & over 10 other private & public investors
- HistoSonics aims to expand its Edison histotripsy system beyond liver tumors to target kidney, pancreas, & prostate indications; it is currently enrolling pts in liver, kidney (HOPE4KIDNEY), & pancreas (GANNON) trials
Ref: Businesswire | Image: HistoSonics | Press Release
Related News:- SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for ~$412M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
